Description
GLP-RT3 | 15 / 20 / 30 mg
BioChain USA · Research use only
⚠
For research use only. Not for human or animal consumption. This compound is sold exclusively for in vitro research, laboratory, and analytical purposes by BioChain USA. It is not a drug, supplement, or therapeutic product of any kind.
What Is GLP-RT3?
GLP-RT3 (also referenced as LY3437943) is an acylated 39-amino acid synthetic peptide engineered as a triple receptor agonist at GIPR (glucose-dependent insulinotropic polypeptide receptor), GLP-1R (glucagon-like peptide-1 receptor), and GCGR (glucagon receptor).
In published research literature, it is used to study multi-receptor incretin and glucagon-axis signaling, energy balance pathways, and lipidation-based peptide engineering strategies that extend exposure duration in experimental models.
GLP-RT3 in Plain Language
A non-technical overview of what GLP-RT3 is, what researchers have studied it for, what early evidence suggests, and what cannot be claimed about it. For research and educational purposes only.
Research-Use Disclaimer. BioChain USA sells GLP-RT3 strictly as a research-use-only chemical. GLP-RT3 is an investigational compound, it has not been approved by the FDA, EMA, or any other regulator for any medical use as of this writing. It is not a drug, dietary supplement, or medical product.
It is not intended for human consumption, medical treatment, veterinary treatment, diagnosis, prevention, or cure of any condition. No statements on this page have been evaluated by the FDA.
At a glance
GLP-RT3 is a lab-made peptide engineered to activate three different metabolic receptors at once, the same general family of receptors that GLP-1 medications like Ozempic and Mounjaro target, but with one additional receptor added in. In research, scientists are studying how this triple-action affects appetite, blood sugar, fat metabolism, and energy use compared with single- and dual-receptor approaches.
It is currently in late-stage drug trials and is not yet FDA-approved. The compound sold here is a research chemical, not a pharmaceutical, and is not for human or animal use.
What it is
GLP-RT3 (Eli Lilly research code LY3437943) is a synthetic peptide engineered to engage three natural gut- and metabolic-hormone receptors at the same time: the GIP receptor, the GLP-1 receptor, and the glucagon receptor. Researchers describe it as a triple agonist, a step beyond dual GIP / GLP-1 agonists like tirzepatide.
The molecule includes a fatty-acid side chain that binds albumin in the bloodstream, which extends its functional half-life and supports a long-acting receptor engagement profile in clinical investigation.
As of this writing, GLP-RT3 is being evaluated in Phase III clinical trials by Eli Lilly for obesity ( It has not received FDA, EMA, or other regulatory approval.
Research areas being investigated
- Triple-agonist pharmacology research: Studied for combined activity at GIP, GLP-1, and glucagon receptors and for how the three signals interact.
- Body weight research: Examined in animal models and Phase II / Phase III human research on chronic weight management.
- Glucose metabolism research: Investigated for effects on insulin secretion, glucagon-receptor-mediated effects on hepatic glucose output, and combined incretin effects on glucose homeostasis.
- Hepatic fat and energy expenditure research: Studied for liver-fat fraction (by MR spectroscopy) and resting energy expenditure endpoints in clinical research.
- Cardiometabolic research: Examined for effects on lipids, blood pressure, and waist circumference.
- Peptide-engineering research: Used as an example of a multi-receptor agonist with engineered fatty-acid acylation for albumin binding and extended half-life.
What the research suggests so far
Animal / preclinical findings. In rodent and primate studies, GLP-RT3 has been described as engaging GIPR, GLP-1R, and glucagon receptors with distinct potencies, and as producing dose-dependent effects on food intake, body weight, glucose handling, and hepatic fat.
Mechanistic discussion in the literature emphasizes the contribution of the glucagon-receptor arm to energy expenditure and hepatic lipid handling, on top of the incretin (GIP / GLP-1) effects on insulin secretion and food intake.
Cell / lab findings. Cell-culture pharmacology has characterized GLP-RT3’s receptor binding and downstream signaling at all three receptors, including cAMP production and β-arrestin recruitment.
Human findings. Phase II clinical research published in 2023 (in adults with obesity, and separately in adults with type 2 diabetes) reported substantial reductions in body weight and HbA1c relative to placebo over the trial period. Phase III research (TRIUMPH, TRANSCEND programs) is ongoing under Eli Lilly sponsorship.
None of this human data supports off-label or non-pharmaceutical use: the data come from a specific investigational pharmaceutical formulation manufactured under regulated conditions and administered under clinical investigation; they do not generalize to research-grade material, to non-medical use, or to populations or conditions outside of those clinical trials.
Limitations of the evidence. Long-term outcome data, including cardiovascular outcomes and durable safety, are not yet established. GLP-RT3 has not been approved by the FDA, EMA, or any other regulator for any indication.
Public-health agencies have warned about non-pharmaceutical compounded or research-grade peptides in this class. Research-grade material is not equivalent to a finished pharmaceutical product in formulation, sterility, dosing accuracy, or oversight.
Research relevance
GLP-RT3 is most often discussed in research involving GIP / GLP-1 / glucagon triple-agonist pharmacology, body-weight regulation, glucose homeostasis and incretin biology, hepatic lipid handling and energy expenditure, and peptide-engineering strategies for multi-receptor agonism. Phase III research is ongoing; results so far are promising in clinical research populations but have not led to regulatory approval as of this writing.
The clinical findings come from an investigational pharmaceutical product administered under clinical-trial supervision and do not, on their own, justify generalized claims about research-grade material.
What cannot be claimed about GLP-RT3
- It cannot be claimed to treat, cure, heal, or prevent any human or animal condition.
- It cannot be claimed to be FDA-approved or to be equivalent to any approved drug.
- It cannot be claimed to treat type 2 diabetes, obesity, prediabetes, metabolic syndrome, or fatty liver disease.
- It cannot be claimed to cause weight loss, suppress appetite, or be used for cosmetic weight management in customers.
- It cannot be claimed to be safe or effective for human or veterinary use.
- It cannot be represented as a dietary supplement.
Summary
GLP-RT3 (LY3437943) is a synthetic triple agonist of the GIP, GLP-1, and glucagon receptors with engineered amino-acid substitutions and fatty-acid acylation for extended half-life. It is studied in research on combined incretin and glucagon-receptor pharmacology, body-weight regulation, glucose homeostasis, and hepatic lipid handling. It is currently in Phase III clinical investigation under Eli Lilly sponsorship for obesity and type 2 diabetes.
It is not FDA-approved or otherwise approved by any regulator as a drug at the time of writing. BioChain USA’s GLP-RT3 is sold strictly as a research-use-only chemical for laboratory investigation. It is not intended for human consumption, medical use, or veterinary use.
Short version
GLP-RT3 is a synthetic triple GIP / GLP-1 / glucagon-receptor agonist currently in Phase III clinical investigation. It is not FDA-approved. Sold for research and laboratory use only.
Source notes
- Coskun T, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist: discovery, pharmacology, and pharmacokinetics. Cell Metab, 2022, pharmacology / discovery report.
- Jastreboff AM, et al. Triple-hormone-receptor agonist GLP-RT3 for obesity: a randomized Phase II trial. N Engl J Med, 2023, Phase II randomized clinical trial in obesity.
- Rosenstock J, et al. GLP-RT3, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a Phase II trial. Lancet, 2023, Phase II randomized clinical trial in type 2 diabetes.
- Sanyal AJ, et al. GLP-RT3 for non-alcoholic fatty liver disease: Phase II analysis. 2024, Phase II analysis on hepatic fat fraction.
- TRIUMPH (NCT05882045) and TRANSCEND clinical trial registry entries, ongoing Phase III trials, ClinicalTrials.gov.
Source types: entry 1 is a pharmacology / discovery study; entries 2, 3, 4 are Phase II randomized clinical trials of an investigational pharmaceutical formulation; entry 5 references Phase III trial registry entries. None of the clinical findings constitute regulatory approval; GLP-RT3 remains investigational.
SEO meta description
GLP-RT3 (LY3437943, research-grade) is a synthetic triple GIP / GLP-1 / glucagon-receptor agonist studied in investigational research on metabolism. Research-use only.
Reminder. BioChain USA sells GLP-RT3 strictly as a research-use-only chemical for qualified laboratory and educational use. It is an investigational compound that is not FDA-approved and is not intended for human consumption, medical treatment, veterinary treatment, diagnosis, prevention, or cure of disease.
Chemical Reference Data
| Molecular Formula | C221H342N46O68 |
|---|---|
| Molecular Weight | ~4,731.3 g/mol |
| Peptide Length | 39 amino acids |
| Structural Classification | Acylated peptide conjugated to a fatty diacid moiety |
| CAS Number | 2381089-83-2 |
Structural Design and Engineering
GLP-RT3 is described in peer-reviewed sources as a single peptide conjugated to a fatty diacid moiety, engineered to activate three metabolic hormone receptors simultaneously: GIP, GLP-1, and glucagon. The structure incorporates non-native residues and a lipid-conjugated side chain designed to influence stability and pharmacokinetic behavior in experimental models.
A frequently cited engineering feature is fatty diacid conjugation, a strategy used in peptide pharmacology to increase albumin association and slow clearance in experimental systems.
BioChain USA does not make medical claims. Research context does not equal clinical outcome data.
Research Applications
GLP-RT3 is used as a research tool to investigate:
- Triple receptor agonism across GIPR, GLP-1R, and GCGR simultaneously
- Receptor potency and signal profiling, including downstream pathway readouts and receptor bias concepts
- Metabolic system modeling, glucose-related signaling, energy intake endpoints, and adiposity-related measures depending on study design
- Peptide engineering, effects of lipidation on receptor engagement duration, clearance dynamics, and biological stability
Some publications describe GLP-RT3 as exhibiting comparatively higher potency at GIPR relative to endogenous ligands, with lower relative potency at GLP-1R and GCGR in specific in vitro assay frameworks. These are study-level findings from the literature, not product claims made by BioChain USA.
Key Research Themes in the Literature
1. Three-Receptor Engagement (GIPR + GLP-1R + GCGR)
GLP-RT3 combines incretin receptor agonism (GIP and GLP-1 pathways) with glucagon receptor agonism, enabling researchers to study how simultaneous activation across three receptors influences:
- Islet hormone dynamics, insulin and glucagon behavior across varying glucose conditions
- Appetite and satiety signaling in mechanistic models
- Energy expenditure and substrate utilization themes in metabolism research
2. Downstream Signaling and Pathway Readouts
Researchers profile downstream effects of receptor activation using readouts including second-messenger signaling, kinase cascades, receptor internalization and trafficking, and gene-expression marker shifts.
A recurring research topic is signal bias, the observation that a given ligand may preferentially activate certain downstream pathways relative to other agonists at the same receptor.
3. Lipidation and Pharmacokinetic Engineering
Peer-reviewed sources describe GLP-RT3 as conjugated to a fatty diacid moiety, a design approach used in peptide pharmacology to extend exposure duration and reduce clearance in experimental systems. This makes GLP-RT3 relevant in studies examining how lipidation affects:
- Receptor engagement duration in vitro
- Tissue distribution and biological persistence
- Degradation risk and stability in biological matrices
4. Clinical Trial Literature Context
GLP-RT3 has been evaluated in clinical research within obesity and cardiometabolic study contexts. Published trial data is cited in the research literature to describe safety and efficacy endpoints observed within controlled study designs. BioChain USA does not represent clinical findings as consumer outcomes. These citations are research literature contexts only.
Certificate of Analysis (COA)
- COA provided where available for the specific batch shipped.
- The batch COA is the authoritative reference for analytical methods, purity data, and lot-specific testing for that shipment.
- COA information is batch-specific and is not interchangeable between lots.
Storage and Handling
General peptide handling guidance for research use:
- Store in a cool, dry, dark environment.
- For extended storage, follow standard peptide handling protocols: cold storage with protection from light and moisture.
- Avoid repeated open-close cycles that introduce humidity to the lyophilized material.
BioChain USA does not provide instructions for human or animal administration.
Frequently Asked Questions
Is this product for human use?
No. Cut Catalyst (GLP-RT3) is not approved or intended for human or veterinary use. It is sold exclusively for in vitro research, laboratory, and analytical purposes. It is not a drug, supplement, or therapeutic product of any kind.
What is GLP-RT3 used for in research?
GLP-RT3 is used to study triple receptor signaling across GIPR, GLP-1R, and GCGR; receptor bias and downstream pathway profiling; metabolic signaling investigation; and lipidation-based peptide engineering. Specific applications depend on the researcher’s study design and objectives.
Do you provide dosing instructions or administration protocols?
No. BioChain USA does not provide dosing guidance, administration instructions, or protocols for human or animal use. Researchers are responsible for designing in vitro study protocols appropriate to their applications and institutional requirements.
Do you provide a Certificate of Analysis (COA)?
Yes, where available. COAs are batch-specific documents reflecting the analytical testing and purity data for that particular lot. The COA included with your order is the authoritative reference for that batch. Availability may vary by lot.
Compliance and Disclaimers
- Sold for research, laboratory, or analytical purposes only.
- Not intended to diagnose, treat, cure, or prevent any disease or condition.
- Not for human or animal consumption.
- Purchaser assumes full responsibility for compliance with all applicable local, state, and federal regulations governing the purchase and use of research compounds.
References & additional GLP-RT3 resources
GLP-RT3 Overview at BioChain USA
This GLP-RT3 product page lists the 30 mg lyophilized vial of the BioChain USA research-grade GLP-RT3 compound.
Every GLP-RT3 lot is independently third-party tested, with a COA available per batch.
GLP-RT3 is supplied strictly for in vitro research use and is not approved for human or animal consumption.
GLP-RT3 Product Imagery
Related BioChain Research Peptides
GLP-RT3 is part of a broader catalog of research-grade peptides at BioChain USA. Each related product is third-party tested.
- Tirzepatide research-grade peptide
- Tesamorelin research-grade peptide
- CJC-1295 + Ipamorelin research-grade peptide
- MOTS-c research-grade peptide
External Peer-Reviewed Research Literature
Investigators studying the GLP-RT3 compound class may consult external research databases for published literature.
- PubMed: GLP-RT3 published research literature
- NCBI PMC: GLP-RT3 open access articles
- PubMed: peptide research literature
GLP-RT3 FAQ
What is GLP-RT3? GLP-RT3 is a research-grade compound supplied by BioChain USA as a lyophilized vial for in vitro laboratory research only.
What vial size does BioChain USA offer? This product page lists the 30 mg vial size.
Is GLP-RT3 tested? Yes. Every GLP-RT3 lot is independently third-party tested and ships with a COA reference when available.
Can GLP-RT3 be used on humans or animals? No. GLP-RT3 is supplied strictly for in vitro research use. It is not approved for human or animal consumption.
How does GLP-RT3 ship? BioChain USA ships GLP-RT3 as a lyophilized powder in a sealed research vial.
Where can researchers find GLP-RT3 published literature? PubMed and NCBI PMC list peer-reviewed studies on the GLP-RT3 compound class.
